Sound Pharma Gets Positive Data from Trial Treating Aminoglycoside-Induced Ototoxicity
Sound Pharmaceuticals will present the Phase 2b STOP Ototoxicity data at the Association for Research in Otolaryngology Midwinter Meeting.
Sound Pharmaceuticals will present the Phase 2b STOP Ototoxicity data at the Association for Research in Otolaryngology Midwinter Meeting.
Two Washington State University (WSU) researchers want to help pharmaceutical companies know if their drugs may cause hearing loss before they hit the market, according to an article on the WSU website.
Cooling the sensitive tissues of the inner ear before and during a cochlear implant surgery may lead to better hearing outcomes, according to a University of Miami Health System and College of Engineering researcher who is leading a collaborative team developing this therapeutic approach.
Researchers identified 41 people with opioid exposure who experienced full or partial hearing loss or tinnitus, likely caused by toxicity to the ear. More than half had used heroin, followed by oxycodone, methadone, and tramadol; 88% had only one known exposure.
Read MoreAccording to the CRL, after recent completion of a pre-approval inspection of the manufacturing facility of our drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK.
Read MoreFindings show that survivors with severe hearing loss are at a significantly increased risk for neurocognitive deficits, independent of what type of therapy they receive.
Read MoreIn an article on “Forbes,” professor and journalist Bruce Y. Lee reviews the evidence currently available regarding the link between COVID-19 and hearing loss.
Read MorePEDMARK is said to be an investigational drug for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to <18 years of age with localized, non-metastatic, solid tumors.
Read MoreSensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a clinical-stage biotech company which specializes...
Read MoreResearchers involved with a qualitative study published in Cancer concluded that clinicians play...
Read MoreFor those companies or individuals who have a concern about hearing damage that may have been...
Read MoreThe proteins, described in a report published June 12 in “eLife,” may hold a key to future therapies to restore hearing in people with irreversible deafness. An article summarizing the research was published on the Johns Hopkins Medicine website.
Read MoreSENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read MoreSENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read MoreSENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read MoreThe book describes major advances in our understanding of the pathogenic processes underlying various forms of hearing loss and the emergence of treatments for deafness.
Read MoreIn Phase 1, CILcare was reportedly able to correlate electrophysiology, manganese-enhanced magnetic resonance imaging (MEMRI), and behavioral assessments that define a preclinical model for detecting tinnitus. In Phase 2, CILcare will adapt the preclinical model to humans.
Read MoreSince 2016, the Ida Institute Research Committee has awarded research grants to projects that investigate the outcomes of using Ida Institute methods and tools and develop evidence to show the effect of person-centered hearing care.
Read More